In Being Patient’s LiveTalk series, Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, shares insights on Eli Lilly’s investigational Alzheimer’s…
We talked with Banner Alzheimer’s Institute Director Pierre Tariot about the most recent results from Eli Lilly’s Alzheimer’s trial for donanemab — what he…
This weekend, new batch of data from the TRAILBLAZER-ALZ trial for Eli Lilly’s Alzheimer’s drug donanemab was released, upholding the treatment’s ability to affect…
While Biogen’s experimental Alzheimer’s treatment aducanumab faced yet another snag recently in its convoluted path toward FDA approval, other drugs companies are catching up:…
Human clinical trials kick off for Protollin, an experimental Alzheimer’s vaccine. After two decades of research and development, Brigham and Women’s Hospital has initiated…
The Centers for Medicare and Medicaid Services will limit Aduhelm coverage to only participants in approved clinical trials. Major U.S. healthcare providers have refused…
Vaccines are one of the greatest medical advances in history. This strategy is now being applied to the treatment and prevention of Alzheimer’s. We…